Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,168 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Terminated Phase 4 Interventional Results available

(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

NCT03796195
View directory record Official record
Conditions
Prostate Cancer, Hot Flashes
Interventions
.5% Bupivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00337077
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
eribulin mesylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
147
States / cities
Scottsdale, Arizona • Monterey, California • Manchester, Connecticut + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Oct 21, 2026, 9:53 AM EDT
Terminated Phase 1 Interventional

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

NCT04267939
View directory record Official record
Conditions
Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
Interventions
Elimusertib (BAY1895344), Niraparib
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Low-Residue Diet in Treating Diarrhea in Patients Receiving Pelvic Radiation Therapy.

NCT00258401
View directory record Official record
Conditions
Cervical Cancer, Diarrhea, Prostate Cancer, Radiation Toxicity, Sarcoma
Interventions
dietary intervention, management of therapy complications, quality-of-life assessment
Dietary Supplement · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
20 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
4,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
113
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

NCT00309894
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim, ketoconazole, therapeutic hydrocortisone
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 120 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 21, 2026, 9:53 AM EDT
Terminated Not applicable Interventional

Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy

NCT04305379
View directory record Official record
Conditions
Prostate Cancer, Urinary Incontinence, Surgery
Interventions
Augmented Bladder Neck Reconstruction, Standard Bladder Neck Reconstruction
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 21, 2026, 9:53 AM EDT
Not yet recruiting Phase 2 Interventional

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

NCT07568756
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer
Interventions
Flotufolastat F18 PET
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Not applicable Interventional

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT06496256
View directory record Official record
Conditions
Prostate Cancer
Interventions
Barrigel, Transrectal Ultrasound
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Chandler, Arizona • Santa Barbara, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Withdrawn Phase 2 Interventional

Telaglenastat + Talazoparib In Prostate Cancer

NCT04824937
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Telaglenastat, Talazoparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Phase 3 Interventional

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

NCT03769766
View directory record Official record
Conditions
Prostate Cancer
Interventions
Curcumin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 89 Years · Male only
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer

NCT03698370
View directory record Official record
Conditions
Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma
Interventions
Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2
Drug · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Multimodal Machine Learning Characterization of Solid Tumors

NCT04687969
View directory record Official record
Conditions
Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Renal Cell Carcinoma (RCC), Prostate Cancer
Interventions
[18F]DCFPyL, PET/MRI scanner
Drug · Radiation
Lead sponsor
Ciprian Catana, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 1 Interventional

EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

NCT00132522
View directory record Official record
Conditions
Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
Interventions
EMD 273066
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 21, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

NCT06212583
View directory record Official record
Conditions
Prostate Cancer, Oligometastatic Disease
Interventions
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT02807805
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Abiraterone Acetate, Niclosamide, Prednisone
Drug
Lead sponsor
Mamta Parikh
Other
Eligibility
19 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Early Phase 1 Interventional

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

NCT05045066
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Locally Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Interventions
Cholecalciferol, Quality-of-Life Assessment, Biospecimen Collection
Dietary Supplement · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

NCT02678351
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Interventions
68Ga-PSMA-11, Magnetic resonance imaging (MRI), Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 21, 2026, 9:53 AM EDT
Recruiting Not applicable Interventional

The Florida ASCENT Study

NCT07042243
View directory record Official record
Conditions
Cancer, Food Deprivation, Food Habits, Food Selection, Colorectal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Gynecologic Cancer, Hematologic Cancer, Skin Cancer, Melanoma, Nutrition Poor, Nutritional Deficiency
Interventions
MyCarePulse and ASCENT PN
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 9:53 AM EDT
Withdrawn Early Phase 1 Interventional

Testing the Synergism of Phytonutrients, Curcumin and Ursolic Acid, to Target Molecular Pathways in the Prostate

NCT04403568
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ursolic Acid, Curcumin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy

NCT00245518
View directory record Official record
Conditions
Hot Flashes
Interventions
Isoflavone, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 21, 2026, 9:53 AM EDT